# A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

> **NCT06880744** · PHASE3 · RECRUITING · sponsor: **AbbVie** · enrollment: 530 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Risankizumab
- **DRUG:** Risankizumab
- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT06880744
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-17
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 530 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06880744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06880744, "A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06880744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*